
CAR-T Therapy- Pipeline Insight, 2024
Description
CAR-T Therapy- Pipeline Insight, 2024
DelveInsight’s, “CAR-T Therapy- Pipeline Insight, 2024” report provides comprehensive insights about 200+ companies and 252+ pipeline drugs in CAR-T Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
CAR-T Therapy: Overview
Chimeric Antigen Receptors (CARs), also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137.
CAR T cell therapy uses T cells engineered with CARs to treat cancer. The premise of CAR T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, and then infuse the resulting CAR T cells into patients to attack their tumors. Cancer Immunotherapy utilizes and enhances the immune system's standard capacity and is considered one of the most promising approaches for treating various diseases (including cancer, autoimmune diseases, and allergic–hypersensitivity reactions) are severe.
Adoptive T-cell transfer (ACT) is a new area of transfusion medicine that involves the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. Three forms of ACT are being developed for cancer therapy; these include tumor-infiltrating lymphocytes (TILs), T-cell receptor (TCR) T-cells, and CAR T-cells. Out of these three, CAR T-cells are the most developed ACTs. ACT was developed to treat advanced cancer with a patient's T-cells, and it has been established over many years through the ex vivo manipulation, expansion, and reinfusion of T-cells. A novel method for generating large numbers of autologous lymphoid cells capable of lysing Rosenberg first described new, noncultured, primary, and metastatic cancer cells in 1980.
Several limitations are being observed with the use of existing technologies for developing CAR-T -cells. These technologies are used for developing CAR-T -cells to target one protein present in tumor cells. Therefore, a new CAR-T -cell is required to be developed for targeting another protein in tumor cells. Toxicity related to use of CAR-T -cells are observed. It is not possible to block the functioning of CAR-T -cells after removal of tumor cells. Off-target toxicity is also observed. Use of second-generation CAR-Cells has caused cytokine release syndrome. Therefore, researchers are developing an organic bi-specific adaptor molecule that has the potential to serve as a bridge between a CAR-T -cell and a cancer cell.
""CAR-T Therapy- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR-T Therapy pipeline landscape is provided which includes the disease overview and CAR-T Therapy treatment guidelines. The assessment part of the report embraces, in depth CAR-T Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence CAR-T Therapy R&D. The therapies under development are focused on novel approaches to treat/improve CAR-T Therapy.
This segment of the CAR-T Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR-T Therapy Emerging Drugs
- CT053: Carsgen Therapeutics
- Descartes-08: Cartesian Therapeutics
- ALLO-501A: Allogene Therapeutics
- CTX110: CRISPR Therapeutics
- IMPT 314: ImmPACT Bio
IMPT-314 and IMPT-514 are based on work by Yvonne Chen, Ph.D., associate professor, and Sarah Larson, M.D., associate clinical professor, both of the University of California, Los Angeles (UCLA). Initial Phase 1 data from a UCLA investigator-led study evaluating the bispecific CAR construct underlying IMPT-314 demonstrated a 91% (10/11) overall response rate, 73% (8/11) complete response rate, 18.2-month median progression free survival, and a well-tolerated safety profile with no cytokine release syndrome above Grade 1 and no neurotoxicity in patients with relapsed or refractory (R/R) non-Hodgkin lymphoma. IMPT-314 is currently being evaluated in the ongoing Phase I/II, multi-center, open-label trial in participants with R/R aggressive B-cell lymphoma. IMPT-314 has received Fast Track Designation from the US Food and Drug Administration for the treatment of R/R aggressive B-cell lymphoma.
- ALLO-715: Allogene Therapeutics
Further product details are provided in the report……..
CAR-T Therapy: Therapeutic Assessment
This segment of the report provides insights about the different CAR-T Therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in CAR-T Therapy
- There are approx. 200+ key companies which are developing the therapies for CAR-T Therapy. The companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
CAR-T Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR-T Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR-T Therapy drugs.
CAR-T Therapy Report Insights
- CAR-T Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CAR-T Therapy drugs?
- How many CAR-T Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR-T Therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR-T Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR-T Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
- CARsgen
- CASI Pharmaceuticals
- Tessa Therapeutics
- Cartesian Therapeutics
- Gracell Bio
- Aurora BioPharma
- Carsgen Therapeutics
- Autolus Limited
- CRISPR Therapeutics
- Allogene Therapeutics
- Verismo Therapeutics
- Arcellx
- Nexcella
- JW Therapeutics
- Janssen Pharmaceuticals
- Chongqing Precision Biotech
- CoImmune, Inc.
- Mustang Bio
- Novartis Pharmaceuticals
- Shanghai Unicar-Therapy Bio-medicine Technology
- Sotio Biotech Inc.
- Beam Therapeutics
- AbCLon
- Nanjing IASO Biotherapeutics
- Autolus
- Beijing Immunochina Medical Science and Technology
- Carsgen Therapeutics
- Orgenesis
- IN8Bio
- Oxford BioMedica
- Zevorcabtagene autoleucel
- CNCT19
- TT11
- Descartes-08
- GC007g
- AU101
- AUTO4
- CAR-GPC3
- CTX110
- ALLO-715
- SynKIR 110
- ACLX 003
- NXC-301
- JWCAR029
- Ciltacabtagene autoleucel
- PCAR-19B
- CIK-CAR.CD19
- MB-102
- CART22 Therapy
- Humanized CD19 CAR T-cells
- BOXR 1030
- BEAM-201
- AT101
- CT 103A
- AUTO1/22
- IM21CART
- CAR-GPC3
- ORGCAR19.22 (CD19.22 CAR-T)
- INB-300
- 3rd CAR-T
Table of Contents
550 Pages
- Introduction
- Executive Summary
- CAR-T Therapy: Overview
- Introduction
- Structure of CAR-T cells
- CARS Generations
- Advantages of CAR T-CELLS
- Adverse Events with CAR T-CELL Therapy
- Limitations of Existing Technologies for CAR T-cells
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- CAR-T Therapy– DelveInsight’s Analytical Perspective
- Late Stage Products (Registered)
- Comparative Analysis
- CT053: Carsgen Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Descartes-08: Cartesian Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ALLO-715: Allogene Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- ACLX 003: Arcellx
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- CAR-T Therapy Key Companies
- CAR-T Therapy Key Products
- CAR-T Therapy- Unmet Needs
- CAR-T Therapy- Market Drivers and Barriers
- CAR-T Therapy- Future Perspectives and Conclusion
- CAR-T Therapy Analyst Views
- CAR-T Therapy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.